Deals, M&A

Salix acquires Santarus for $2.6 billion

Posted on 11 November 2013

Tags: , , ,

Salix Pharmaceuticals acquires specialty pharma, Santarus for a whopping $2.6 billion cash transaction. 

Salix Pharmaceuticals and Santarus have entered into a definitive merger agreement under which Salix acquires all of the outstanding common stock of Santarus for $32.00 per share in cash (without interest).

The all-cash transaction values Santarus at approximately $2.6 billion.

The combined company is expected to have a leading position with a strong portfolio of 22 marketed products, including: XIFAXAN, UCERIS, GLUMETZA, APRISO, ZEGERID, MOVIPREP, RELISTOR, SOLESTA, FULYZAQ, CYCLOSET and FENOGLIDE.

Salix intends to finance the transaction with a combination of approximately $800 million cash on hand and $1.95 billion in committed financing from Jefferies Finance.

Jefferies Finance also has committed to provide an additional $150 million revolving credit facility.

Read the full news release at Salix



Report: Merger and Acquisition Terms and Agreements

Report: Partnering Deals and Alliances with Novartis

Report: Partnering Deals and Alliances with Roche

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply